These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 37605836)

  • 1. The utility of rested prolactin sampling in the evaluation of hyperprolactinaemia.
    Wilkinson T; Li B; Soule S; Hunt P
    Intern Med J; 2024 Feb; 54(2):307-311. PubMed ID: 37605836
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Importance of cannulated prolactin test in the definition of hyperprolactinaemia.
    Whyte MB; Pramodh S; Srikugan L; Gilbert JA; Miell JP; Sherwood RA; McGregor AM; Aylwin SJ
    Pituitary; 2015 Jun; 18(3):319-25. PubMed ID: 24879500
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A cannulated prolactin series reduces the need for further investigations in women with infertility and lowers the number of false positive screening prolactin measurements.
    Searle L; McDowell S; Willink R; Krebs J
    Aust N Z J Obstet Gynaecol; 2021 Dec; 61(6):949-954. PubMed ID: 34357589
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Macroprolactin screening in 464 patients with hyperprolactinaemia.
    Lim MH; Ho CKM
    Malays J Pathol; 2022 Aug; 44(2):261-267. PubMed ID: 36043589
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interference by macroprolactin in assays for prolactin: will the
    Fahie-Wilson MN; Cobbaert CM; Horvath AR; Smith TP
    Clin Chem Lab Med; 2022 Aug; 60(9):1350-1355. PubMed ID: 35704648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitative adjustment for macroprolactin is an integral part of laboratory assessment of hyperprolactinaemia.
    Heald AH; Blantern E; Anderson SG; Radford D; Qureshi Z; Nair S; Waldron J; Davies M; McCulloch A; Kane J
    Exp Clin Endocrinol Diabetes; 2012 Jun; 120(6):376-80. PubMed ID: 22576261
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The prevalence of hyperprolactinaemia and association with markers of autoimmune thyroid disease in survivors of the Whickham Survey cohort.
    Vanderpump MP; French JM; Appleton D; Tunbridge WM; Kendall-Taylor P
    Clin Endocrinol (Oxf); 1998 Jan; 48(1):39-44. PubMed ID: 9509066
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The epidemiology of hyperprolactinaemia over 20 years in the Tayside region of Scotland: the Prolactin Epidemiology, Audit and Research Study (PROLEARS).
    Soto-Pedre E; Newey PJ; Bevan JS; Greig N; Leese GP
    Clin Endocrinol (Oxf); 2017 Jan; 86(1):60-67. PubMed ID: 27434534
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management.
    Haddad PM; Wieck A
    Drugs; 2004; 64(20):2291-314. PubMed ID: 15456328
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Presentations of Drug-Induced Hyperprolactinaemia: A Literature Review.
    Junqueira DR; Bennett D; Huh SY; Casañas I Comabella C
    Pharmaceut Med; 2023 Mar; 37(2):153-166. PubMed ID: 36800148
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determination of prolactin: the macroprolactin problem.
    Fahie-Wilson M; Smith TP
    Best Pract Res Clin Endocrinol Metab; 2013 Oct; 27(5):725-42. PubMed ID: 24094642
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Medical causes and consequences of hyperprolactinaemia. A context for psychiatrists.
    Holt RI
    J Psychopharmacol; 2008 Mar; 22(2 Suppl):28-37. PubMed ID: 18477618
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hyperprolactinaemia and antipsychotic therapy in schizophrenia.
    Hummer M; Huber J
    Curr Med Res Opin; 2004; 20(2):189-97. PubMed ID: 15006013
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interpretation of Serum Gonadotropin Levels in Hyperprolactinaemia.
    Abbara A; Clarke SA; Nesbitt A; Ali S; Comninos AN; Hatfield E; Martin NM; Sam AH; Meeran K; Dhillo WS
    Neuroendocrinology; 2018; 107(2):105-113. PubMed ID: 29660734
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Macroprolactinaemia, the major unknown in the differential diagnosis of hyperprolactinaemia.
    Cattaneo F; Kappeler D; Müller B
    Swiss Med Wkly; 2001 Mar; 131(9-10):122-6. PubMed ID: 11416967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Screening for macroprolactinaemia and pituitary imaging studies.
    Hauache OM; Rocha AJ; Maia AC; Maciel RM; Vieira JG
    Clin Endocrinol (Oxf); 2002 Sep; 57(3):327-31. PubMed ID: 12201824
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Macroprolactinaemia].
    Kostrzak A; Meczekalski B
    Pol Merkur Lekarski; 2010 Jul; 29(169):47-9. PubMed ID: 20712249
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Hyperprolactinaemia and bone mineral density].
    Kostrzak A; Męczekalski B
    Pol Merkur Lekarski; 2015 Aug; 39(230):122-5. PubMed ID: 26319389
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The prevalence of hyperprolactinaemia in subfertile ovulatory women and its impact on fertility treatment outcome.
    Wojcik M; Amer S; Jayaprakasan K
    J Obstet Gynaecol; 2022 Aug; 42(6):2349-2353. PubMed ID: 35473513
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ectopic hyperprolactinaemia due to a malignant uterine tumor resembling ovarian sex cord tumors (UTROCST).
    Dimitriadis GK; Wajman DS; Bidmead J; Diaz-Cano SJ; Arshad S; Bakhit M; Lewis D; Aylwin SJB
    Pituitary; 2020 Dec; 23(6):641-647. PubMed ID: 32857272
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.